Alterity Therapeutics (NASDAQ: ATHE) reports expiry of 91M options
Rhea-AI Filing Summary
Alterity Therapeutics Limited reports that 91,392,720 unquoted options with ASX code ATHAAD, exercisable at $0.032 and expiring on 6 January 2026, have lapsed without being exercised or converted. No consideration was paid in connection with this expiry.
Following this change, the company’s issued capital on ASX comprises 10,875,416,329 ordinary fully paid shares (ATH), along with quoted options ATHO (option expiring 31 August 2026) totaling 931,232,089 and ATHOA (option expiring 26 February 2027) totaling 1,222,300,911. Various classes of unquoted options remain on issue, while the ATHAAD class now has zero securities outstanding.
Positive
- None.
Negative
- None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 7, 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
| 99.1 | Notification of cessation of securities - ATH |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | ||
| By: | /s/ Julian Babarczy | |
| Julian Babarczy | ||
| Chairman | ||
Date: January 7, 2026
2
Exhibit 99.1
 |
Appendix 3H - Notification of cessation of securities |
Announcement Summary
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
Wednesday January 07, 2026
Details of +securities that have ceased
| ASX +security code |
Security description | Number of +securities that have ceased |
The +securities have ceased due to |
Date of cessation | ||||
| ATHAAD | OPTION EXPIRING 06-JAN-2026 EX $0.032 |
91,392,720 | Expiry of option or other convertible security without exercise or conversion | 06/01/2026 |
Refer to next page for full details of the announcement
| Appendix 3H - Notification of cessation of securities | 1/4 |
|
Appendix 3H - Notification of cessation of securities |
Part 1 - Announcement Details
| 1.1 Name of +Entity | |
| ALTERITY THERAPEUTICS LIMITED | |
| We (the entity named above) provide the following information about our issued capital. |
| 1.2 Registered Number Type | Registration Number | ||
| ABN | 37080699065 |
| 1.3 ASX issuer code | |
| ATH | |
| 1.4 The announcement is | |
| New announcement | |
| 1.5 Date of this announcement | |
| 7/1/2026 |
| Appendix 3H - Notification of cessation of securities | 2/4 |
|
Appendix 3H - Notification of cessation of securities |
Part 2 - Details of +equity securities or +debt securities that have ceased
| ASX +Security Code and Description | |
| ATHAAD : OPTION EXPIRING 06-JAN-2026 EX $0.032 | |
| Unquoted +equity securities that have ceased | |
| Number of securities that have ceased | |
| 91,392,720 | |
| Reason for cessation | |
| Expiry of option or other convertible security without exercise or conversion |
| Date of cessation | Is the entity paying any consideration for the cessation? | ||
| 6/1/2026 | No |
Any other information the entity wishes to notify to ASX about the cessation?
| Appendix 3H - Notification of cessation of securities | 3/4 |
|
Appendix 3H - Notification of cessation of securities |
Part 3 - Issued capital following changes
Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:
The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)
| Total number of | ||||
| ASX +security code and description | +securities on issue | |||
| ATH : ORDINARY FULLY PAID | 10,875,416,329 | |||
| ATHO : OPTION EXPIRING 31-AUG-2026 | 931,232,089 | |||
| ATHOA : OPTION EXPIRING 26-FEB-2027 | 1,222,300,911 | |||
3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)
| Total number of | ||||
| ASX +security code and description | +securities on issue | |||
| ATHAAE : OPTION EXPIRING 29-NOV-2026 EX $0.0375 | 10,000,000 | |||
| ATHAAG : OPTION EXPIRING 29-NOV-2026 EX $0.0238 | 11,500,000 | |||
| ATHAE : OPTION EXPIRING 08-AUG-2030 EX $0.013 | 11,500,000 | |||
| ATHAF : OPTION EXPIRING 08-AUG-2030 EX USD 0.0086 | 312,400,200 | |||
| ATHAD : OPTION EXPIRING 01-JUL-2030 EX $0.01 | 15,000,000 | |||
| ATHAAK : OPTION EXPIRING 30-DEC-2027 EX $0.01 | 170,000,000 | |||
| ATHAAH : OPTION EXPIRING 19-DEC-2026 EX $0.0105 | 8,000,000 | |||
| ATHAB : OPTION EXPIRING 13-MAR-2029 EX US$0.0031 | 62,500,000 | |||
| ATHAA : OPTION EXPIRING 13-MAR-2029 EX $0.004 | 20,166,667 | |||
| ATHAC : OPTION EXPIRING 21-MAR-2029 EX US$0.003 | 40,000,200 | |||
| ATHAAD : OPTION EXPIRING 06-JAN-2026 EX $0.032 | 0 | |||
Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.
| Appendix 3H - Notification of cessation of securities | 4/4 |
FAQ
What did Alterity Therapeutics (ATHE) disclose in this Form 6-K?
Alterity Therapeutics disclosed that a series of unquoted options with ASX code ATHAAD, expiring on 6 January 2026 with a $0.032 exercise price, have ceased due to expiry without exercise or conversion, and updated its issued capital figures.
How many Alterity Therapeutics ATHAAD options expired?
A total of 91,392,720 unquoted ATHAAD options, expiring on 6 January 2026 with an exercise price of $0.032, have expired without being exercised or converted.
Did Alterity Therapeutics pay any consideration for the cessation of these options?
No. The disclosure states that the entity is not paying any consideration for the cessation of the 91,392,720 ATHAAD options.
What is Alterity Therapeutics’ ordinary share capital after the option expiry?
After the ATHAAD option expiry, Alterity Therapeutics has 10,875,416,329 ordinary fully paid shares on issue under ASX code ATH.
What other quoted options does Alterity Therapeutics have on issue?
The company has quoted options including ATHO (option expiring 31 August 2026) with 931,232,089 on issue and ATHOA (option expiring 26 February 2027) with 1,222,300,911 on issue.
Does Alterity Therapeutics still have any ATHAAD options outstanding?
No. Following the reported expiry, the ATHAAD option class now has zero securities on issue.
What unquoted options remain outstanding for Alterity Therapeutics?
Unquoted options on issue include various series such as ATHAAE (10,000,000), ATHAAG (11,500,000), ATHAE (11,500,000), ATHAF (312,400,200), ATHAD (15,000,000), ATHAAK (170,000,000), ATHAAH (8,000,000), ATHAB (62,500,000), ATHAA (20,166,667), and ATHAC (40,000,200).
